Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference CallGlobeNewsWire • Thursday
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026GlobeNewsWire • 10/24/26
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026GlobeNewsWire • 10/23/26
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026GlobeNewsWire • 10/05/26
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United StatesGlobeNewsWire • 09/30/26
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks TranscriptSeeking Alpha • 09/09/26
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast CancerGlobeNewsWire • 08/26/26
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELCPRNewsWire • 08/07/26
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference CallGlobeNewsWire • 08/06/26
Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 08/04/26
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsBusiness Wire • 08/04/26
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS LawBusiness Wire • 08/02/26
CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the FirmPRNewsWire • 07/31/26
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELCPRNewsWire • 07/30/26
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast CancerGlobeNewsWire • 07/30/26